Novo Nordisk shares fell up to 8% after CEO Maziar Mike Doustdar presented a long-term growth strategy at the company's Capital Markets Day. Investors reacted coolly to plans targeting $23 billion in pipeline sales by 2035 and five new blockbuster launches by 2030. The strategy aims to counter the 2032 U.S. patent expiration of blockbuster semaglutide and intense market share pressure from chief rival Eli Lilly, whose tirzepatide franchise continues to erode Novo's dominant position.
Capital Markets Day investor disappointment
- ▪Novo Nordisk CEO Maziar Mike Doustdar acknowledged investor pressure at the Capital Markets Day, stating that the company must convince investors of its bright future.
- ▪Novo Nordisk shares fell between 7% and 8% on September 21, 2026, following the company's Capital Markets Day presentation in London.
- ▪Novo Nordisk announced a reduction in its global workforce to 66,000 employees, down 15% from 77,000 two years prior, following 9,000 previously announced layoffs and an additional 4,000 departures.
Semaglutide patent expiration challenge
- ▪Novo Nordisk's active ingredient semaglutide, used in Wegovy and Ozempic, is scheduled to lose key patent exclusivity in the United States starting in 2032.
- ▪Novo Nordisk CEO Maziar Mike Doustdar identified the upcoming loss of patent exclusivity for semaglutide as a major challenge that will bring price pressure and intense competition.
Consumer Rx segment strategy
- ▪Novo Nordisk plans to develop a 'Consumer Rx' business segment to deliver prescription medications directly to consumers in areas like pain, addiction, and women's health.
- ▪Novo Nordisk CEO Maziar Mike Doustdar clarified that the Consumer Rx initiative is not an entry into the over-the-counter market or consumer care.
Multi-blockbuster pipeline targets
- ▪Novo Nordisk's pipeline targets for expansion beyond diabetes and obesity include blood and endocrine disorders, liver diseases, and cardiovascular disease.
- ▪Novo Nordisk plans to expand its manufacturing capacity to serve 10 times the current 1.5 million patients taking its oral Wegovy pill by the end of the decade.
- ▪Novo Nordisk aims to launch more than five multi-blockbuster drugs by 2030 to generate over $23 billion in risk-adjusted pipeline sales by 2035.
Eli Lilly competitive pressure
- ▪Eli Lilly's tirzepatide franchise has taken market share from Novo Nordisk's Ozempic and Wegovy, contributing to Eli Lilly shares rising 52% while Novo Nordisk shares fell 27% over the preceding 12 months.
- ▪BMO Capital Markets noted that CagriSema's superiority over a low 5 mg dose of tirzepatide in type 2 diabetes is less impactful because tirzepatide previously beat CagriSema in obesity trials.
- ▪Novo Nordisk's next-generation weight-loss candidate CagriSema demonstrated a 12.4% weight loss compared to 9.1% for Eli Lilly's tirzepatide at 60 weeks in the Phase 3 REIMAGINE 5 trial.
Debatable claims
- ▪Novo Nordisk should deliver prescription medications directly to consumers
- ▪Novo Nordisk's workforce reductions are necessary to maintain its competitiveness
Story comments
Loading comments…